Navigation Links
Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept
Date:2/5/2008

Following its Launch in 2010, Myriad Genetics' Flurizan Will Earn a 23% Patient Share in the United States, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on delaying the progression from mild cognitive impairment to Alzheimer's disease is the attribute that most influences neurologists' prescribing decisions in the treatment of mild cognitive impairment. Clinical trial data and expert opinion shows that Myriad Genetics' Flurizan has advantages in this attribute over Eisai/Pfizer's Aricept/Bracco's Memac, the current sales leader and gold standard therapy for mild cognitive impairment.

The new report entitled Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Opportunity finds that, following its launch in 2010, Flurizan will replace Aricept as the gold standard for mild cognitive impairment. Surveyed U.S. neurologists indicate that they would prescribe Flurizan to 20% of their patients with mild cognitive impairment and the report forecasts that Flurizan will earn a 23% patient share in the U.S. market in 2016.

"Clinical trial data suggests that Flurizan has disease-modifying properties, an asset that interviewed experts expect will make the drug more effective at delaying the onset of Alzheimer's disease than currently available drugs," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "Flurizan's safety and tolerability profile is also better than other emerging competitors, and this, along with its efficacy, will make it the gold standard in the treatment of mild cognitive impairment in 2016."

About the Report

Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Op
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. DNA sensors found to be an effective artificial nose
3. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
4. Job-related stress: NIST demonstrates fatigue effects in silicon
5. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
6. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
9. New nanoparticle vaccine is more effective but less expensive
10. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
11. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/24/2014)... PHILADELPHIA , November 24, 2014 ... Reference Workflow, honored for dynamic leadership skills, business acumen ... scientific, technical and medical information products and services, congratulates ... Manager for Clinical Reference and Workflow, Elsevier Clinical Solutions, ... Women Worth Watching ® Awards issue of ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
(Date:11/22/2014)... 22, 2014 The “Chiral Chromatography ... by Material (Metal, Glass, Plastic), by Application [GC, ... - Forecast to 2018” analyses and studies the ... North America, Europe, Asia, and Rest of the ... 15 figures spread through 135 pages and in-depth ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... , , , , ... Co., Inc., (NYSE Amex: TPI ), a manufacturer and ... Chengdu, China , today announced that it expects operational ... of Medicine,and Medical Services by the Chinese government. , ...
... HUNTINGTON BEACH, California and ... leader in molecular cancer diagnostics, announced today that,it has received ... ,Department of Health. The New York State permit ... breast cancer recurrence,test. , With this ...
... , , , , , , , , ... 8 QIAGEN,(NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and exclusive licence for,biomarker PI3K from Johns Hopkins University ... in the PI3K gene could,be a key biomarker for use as ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services 2Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services 3Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists 2QIAGEN Acquires Exclusive Licence for Key PI3K gene 2QIAGEN Acquires Exclusive Licence for Key PI3K gene 3QIAGEN Acquires Exclusive Licence for Key PI3K gene 4
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... WASHINGTON, April 7, 2011 Metabolism encompasses the ... of as two complementary systems: one that breaks down ... energy to produce the building blocks cells need to ... it,s not surprising that metabolic dysfunctions can lead to ...
... a marker of sleepiness or boredom. For chimpanzees, it ... between individuals. New research at the Yerkes National ... empathy, the mechanism thought to underlie contagious yawning, in ... show how social biases strengthen or weaken empathy. ...
... study of a new method for preventing premature birth in ... Ultrasound in Obstetrics & Gynecology , shows that the ... peer-reviewed findings were led by the Perinatology Research Branch of ... University School of Medicine at Hutzel Hospital in Detroit. The ...
Cached Biology News:At EB2011: The role of metabolism in disease 2Chimpanzees' contagious yawning evidence of empathy, not just sleepiness, study shows 2Major breakthrough in preventing premature birth announced by NIH/WSU 2Major breakthrough in preventing premature birth announced by NIH/WSU 3
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
...
Biology Products: